HUP9900609A2 - Cefditoren pivoxilt tartalmazó, orálisan beadható antibakteriális kompozíció - Google Patents

Cefditoren pivoxilt tartalmazó, orálisan beadható antibakteriális kompozíció

Info

Publication number
HUP9900609A2
HUP9900609A2 HU9900609A HUP9900609A HUP9900609A2 HU P9900609 A2 HUP9900609 A2 HU P9900609A2 HU 9900609 A HU9900609 A HU 9900609A HU P9900609 A HUP9900609 A HU P9900609A HU P9900609 A2 HUP9900609 A2 HU P9900609A2
Authority
HU
Hungary
Prior art keywords
stone
water
cefditoren pivoxil
oral administration
composition
Prior art date
Application number
HU9900609A
Other languages
English (en)
Inventor
Kenichi Abe
Toshihiro Kikkoji
Chikako Murakami
Masato Ota
Hiroyuki Yamaguchi
Original Assignee
Meiji Seika Kaisha, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha, Ltd. filed Critical Meiji Seika Kaisha, Ltd.
Publication of HUP9900609A2 publication Critical patent/HUP9900609A2/hu
Publication of HUP9900609A3 publication Critical patent/HUP9900609A3/hu
Publication of HU224922B1 publication Critical patent/HU224922B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

A találmány őrális beadásra alkalmas új, antibakteriális kőmpőzícióravőnatkőzik, amely cefditőren pivőxil és egy vízőldható kazeinsókeverékét tartalmazza. A kőmpőzícióból, amelyben gyengébb a cefditőrenpivőxil keserű íze, a cefditőren pivőxil vízben könnyebben őldódik ki,és nagyőbb százalékős kiőldódás érhető el a cefditőren pivőxil vízzelvaló kiőldásakőr. A kőmpőzíció őrális beadásakőr a cefditőrenkőmpőnensnagymértékben felszívódik az emésztőcsatőrnában. A kőmpőzícióban acefditőren pivőxil - kazeinsó tömegarány előnyösen 1 : 0,1 és 1 : 4közötti. A találmány másődik váltőzata szerint az előbbi kőmpőzíciótővábbi összetevőként egy vízőldható pőlifőszfőrsavas sót tartalmaz.Ezáltal a cefditőrenpivőxil-kőmpőnens nagymértékű vízőldhatósága akkőris megmarad, ha a kőmpőzíciót szélsőséges körülmények között tárőlják. ŕ
HU9900609A 1995-10-13 1996-10-14 Antibacterial composition of cefditoren pivoxil for oral administration HU224922B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26584795 1995-10-13
PCT/JP1996/002967 WO1997013516A1 (fr) 1995-10-13 1996-10-14 Composition antibacterienne administree par voie orale

Publications (3)

Publication Number Publication Date
HUP9900609A2 true HUP9900609A2 (hu) 1999-07-28
HUP9900609A3 HUP9900609A3 (en) 2001-04-28
HU224922B1 HU224922B1 (en) 2006-04-28

Family

ID=17422903

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900609A HU224922B1 (en) 1995-10-13 1996-10-14 Antibacterial composition of cefditoren pivoxil for oral administration

Country Status (16)

Country Link
US (1) US5958915A (hu)
EP (1) EP0862915B1 (hu)
KR (1) KR100311576B1 (hu)
CN (1) CN1102046C (hu)
AR (1) AR004014A1 (hu)
AT (1) ATE214930T1 (hu)
BR (1) BR9610836A (hu)
CA (1) CA2234426C (hu)
DE (1) DE69620220T2 (hu)
ES (1) ES2174109T3 (hu)
HK (1) HK1016477A1 (hu)
HU (1) HU224922B1 (hu)
MX (1) MX9802849A (hu)
PT (1) PT862915E (hu)
TW (1) TW458778B (hu)
WO (1) WO1997013516A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1051978E (pt) * 1998-01-07 2012-11-20 Meiji Seika Pharma Co Ltd Composições de cefalosporina amorfa cristalograficamente estável e processo para a sua produção
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
WO2002041887A1 (fr) * 2000-11-21 2002-05-30 Kyorin Pharmaceutical Co., Ltd. Preparations seches de sirop
US7125565B2 (en) 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
EP1401402B1 (en) 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
AUPS303202A0 (en) * 2002-06-20 2002-07-11 Pacific Biolink Pty Limited Protein based oral lubricant
KR101019769B1 (ko) 2002-10-02 2011-03-04 메이지 세이카 가부시키가이샤 경구 흡수성이 개선된 항균성 약제학적 조성물
ATE539738T1 (de) * 2003-10-08 2012-01-15 Meiji Seika Pharma Co Ltd Nichtkristalline antibakterielle zusammensetzung mit cefditoren-pivoxil
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
EP2401997B1 (en) 2004-11-16 2016-08-24 3M Innovative Properties Company Dental compositions with calcium phosphorus releasing glass
CN101098673B (zh) 2004-11-16 2012-02-29 3M创新有限公司 包括磷酸盐的牙科填料和组合物
EP1811944B1 (en) 2004-11-16 2010-09-08 3M Innovative Properties Company Compositions including a caseinate treated dental filler
CN101115459B (zh) 2004-11-16 2012-03-21 3M创新有限公司 包括含磷表面处理的牙科填料
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
US8790707B2 (en) 2008-12-11 2014-07-29 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
US20130143857A1 (en) * 2010-07-23 2013-06-06 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105663058A (zh) * 2016-02-01 2016-06-15 济南康和医药科技有限公司 一种头孢妥仑匹酯纳米粒药物制剂及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936609A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS59184122A (ja) * 1983-03-31 1984-10-19 Nitto Electric Ind Co Ltd アクリル系膏体
JPS60102168A (ja) * 1983-11-08 1985-06-06 Tsukishima Shokuhin Kogyo Kk エイコサペンタエン酸強化乳化物及び食品の製造方法
IE58487B1 (en) * 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH0635394B2 (ja) * 1989-02-28 1994-05-11 雪印乳業株式会社 薬物の溶解性および吸収性の改善方法
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤

Also Published As

Publication number Publication date
KR100311576B1 (ko) 2001-12-28
DE69620220D1 (de) 2002-05-02
BR9610836A (pt) 1999-07-13
CA2234426C (en) 2003-07-08
CN1102046C (zh) 2003-02-26
PT862915E (pt) 2002-09-30
EP0862915A1 (en) 1998-09-09
AR004014A1 (es) 1998-09-30
EP0862915B1 (en) 2002-03-27
MX9802849A (es) 1998-11-30
CA2234426A1 (en) 1997-04-17
HUP9900609A3 (en) 2001-04-28
ATE214930T1 (de) 2002-04-15
US5958915A (en) 1999-09-28
ES2174109T3 (es) 2002-11-01
DE69620220T2 (de) 2002-11-28
HU224922B1 (en) 2006-04-28
CN1202110A (zh) 1998-12-16
EP0862915A4 (en) 1998-11-11
TW458778B (en) 2001-10-11
HK1016477A1 (en) 1999-11-05
WO1997013516A1 (fr) 1997-04-17
KR19990064137A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
HUP9900609A2 (hu) Cefditoren pivoxilt tartalmazó, orálisan beadható antibakteriális kompozíció
BR9916835A (pt) Composição de galantamina de liberação controlada
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
BG104644A (en) Novel macrolides
RU96120090A (ru) Сублингвальная или трансбуккальная фармацевтическая композиция
HUP0300731A2 (hu) Valzartan-sók, eljárás elżállításukra és az azokat tartalmazó gyógyszerkészítmények
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
PL348492A1 (en) Novel alpha-crystalline form of t-butylamine salt of perindopril, method of obtaining same and pharmacological compositions containing it
HUP0201907A2 (hu) Időzített kettős hatóanyag-leadású dózisformák, amelyek rövid ideig ható altatót vagy annak sóját tartalmazzák
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
WO2003000692A3 (en) Oxytocin agonists
HUP0001922A2 (hu) Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
MY119090A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
HUP0402006A2 (hu) Eljárás ibuprofen kristályok képzésére és ezek alkalmazása gyógyszerkészítmények előállítására
HUP0002106A2 (hu) Transz-5-klór-2,3,3a,12b-tetrahidro-2-metil-1H-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol aromás szulfonátjai és az ezt tartalmazó gyógyszerkészítmények
AP9801377A0 (en) Tricyclic erythromycin derivatives.
EP1285660A4 (en) ZINC SUPPLEMENTARY COMPOSITIONS FOR ORAL ADMINISTRATION
CA2477773A1 (en) A stable diclofenac-tromethamine composition for the topical treatment of oropharyngeal cavity disorders
FR2678836B1 (fr) Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MEIJI SEIKA PHARMA CO., LTD., JP

Free format text: FORMER OWNER(S): MEIJI SEIKA KAISHA, LTD., JP